Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health (NYSE:HIMS) had its target price boosted by equities researchers at Deutsche Bank Aktiengesellschaft from $23.00 to $27.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 19.00% from the company’s current price.

A number of other research firms have also recently issued reports on HIMS. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Bank of America upped their price target on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. TD Cowen lifted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average price target of $21.00.

Hims & Hers Health Stock Down 3.9 %

Shares of NYSE HIMS traded down $0.93 during midday trading on Wednesday, reaching $22.69. The company had a trading volume of 7,731,858 shares, compared to its average volume of 8,631,039. The firm’s fifty day moving average price is $18.57 and its 200-day moving average price is $18.33. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74. The stock has a market cap of $4.87 billion, a PE ratio of 53.68 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) earnings per share. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health will post 0.22 EPS for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the transaction, the insider now directly owns 176,952 shares in the company, valued at approximately $2,919,708. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the transaction, the insider now directly owns 193,980 shares of the company’s stock, valued at approximately $4,306,356. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the transaction, the insider now owns 176,952 shares in the company, valued at approximately $2,919,708. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 854,547 shares of company stock worth $15,987,230. 17.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. Quest Partners LLC raised its position in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares during the last quarter. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Arizona State Retirement System lifted its position in Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Victory Capital Management Inc. boosted its holdings in Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.